Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.53 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028171 | 0.98 | PLCD1 (0.55) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL486814 | 0.96 | PLCD1 (0.56) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL3614161 | 0.94 | PLCD1 (0.59) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL487698 | 0.90 | PLCD1 (0.44) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL1270689 | 0.90 | PLCD1 (0.44) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20500226 | 0.85 | PLCD1 (0.48) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL2028172 | 0.85 | F2 (0.51) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL10140249 | 0.85 | CNR2 (0.66) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL30165784 | 0.85 | CNR2 (0.66) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL28352827 | 0.84 | TDP1 (0.50) | F2PRSS1PRSS2PRSS3TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | claimed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | claimed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | claimed |
| US-10568835-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-02-25 | — | — | US | claimed |
| EP-3391876-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2018-10-24 | — | — | EP | claimed |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. | 2015-05-07 | — | — | US | claimed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | claimed |
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | claimed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010080976-A1 | INSULIN THERAPIES FOR THE TREATMENT OF DIABETES, DIABETES RELATED AILMENTS, AND/OR DISEASES OR CONDITIONS OTHER THAN DIABETES OR DIABETES RELATED AILMENTS | SDG, INC. (AN OHIO CORPORATION) (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568835-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | F2 2636/4885PRSS1 981/4885PRSS2 858/4885 |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | F2 2252/4885PRSS1 1301/4885PRSS2 609/4885 |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | F2 2498/4885PRSS1 2887/4885PRSS2 3300/4885 |
| US-20150125518-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | F2 2636/4885PRSS1 981/4885PRSS2 858/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | F2 2252/4885PRSS1 1301/4885PRSS2 609/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | F2 2636/4885PRSS1 981/4885PRSS2 858/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | F2 2636/4885PRSS1 981/4885PRSS2 858/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | F2 2357/4885PRSS1 845/4885PRSS2 302/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | F2 2636/4885PRSS1 981/4885PRSS2 858/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | F2 1894/4885PRSS1 4150/4885PRSS2 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.